We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Castle Biosciences presented new data from a study of its DecisionDx melanoma test, showing it improved predictions of individual recurrence risk and sentinel lymph node positivity by measuring the expression of 31 genes from the primary tumor.